Page last updated: 2024-10-24

very-low-density lipoprotein particle remodeling

Definition

Target type: biologicalprocess

The acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]

Very-low-density lipoprotein (VLDL) particle remodeling is a complex process that involves the transformation of VLDL particles into smaller, denser particles, primarily low-density lipoprotein (LDL) and high-density lipoprotein (HDL). It occurs in the bloodstream and involves various enzymes, proteins, and lipid components.

**Step 1: VLDL Secretion from Liver:**
VLDL is synthesized and secreted by the liver, containing primarily triglycerides, cholesterol esters, and apolipoproteins, including apoB-100, apoE, and apoC-II.

**Step 2: Triglyceride Hydrolysis:**
In the bloodstream, lipoprotein lipase (LPL), an enzyme attached to capillary walls, hydrolyzes triglycerides in VLDL particles, releasing free fatty acids. This process reduces VLDL size and increases its density.

**Step 3: Cholesterol Ester Transfer Protein (CETP) Activity:**
CETP facilitates the transfer of cholesterol esters from VLDL to HDL, enriching HDL with cholesterol and reducing VLDL cholesterol content. This exchange contributes to the further reduction in VLDL size.

**Step 4: Formation of Intermediate Density Lipoproteins (IDL):**
As VLDL loses triglycerides, it becomes denser and transforms into IDL particles. IDLs are smaller and denser than VLDL, but still contain significant amounts of triglycerides and cholesterol.

**Step 5: IDL Metabolism:**
IDLs can be further metabolized through two pathways:
- **Catabolism:** IDL can be taken up by the liver directly, where its cholesterol esters are hydrolyzed and cholesterol is released.
- **Conversion to LDL:** IDL can undergo additional lipolysis and removal of triglycerides, converting into LDL particles.

**Step 6: LDL Formation:**
LDL, the primary cholesterol carrier in the blood, is formed from IDL through further triglyceride hydrolysis and enrichment with cholesterol esters.

**Step 7: HDL Metabolism:**
HDL particles, enriched with cholesterol from VLDL and IDL, can either be taken up by the liver (reverse cholesterol transport) or interact with other lipoproteins, continuing the cholesterol transfer process.

The entire process of VLDL remodeling is tightly regulated by various factors, including dietary fat intake, genetic predisposition, and hormonal influences. Dysregulation of this process can contribute to the development of cardiovascular disease by increasing LDL levels and decreasing HDL levels in the blood.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Cholesteryl ester transfer proteinA cholesteryl ester transfer protein that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11597]Homo sapiens (human)
Hepatic triacylglycerol lipaseA hepatic triacylglycerol lipase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11150]Homo sapiens (human)
Lipoprotein lipaseA lipoprotein lipase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P06858]Homo sapiens (human)
Phosphatidylcholine-sterol acyltransferaseA phosphatidylcholine-sterol acyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04180]Homo sapiens (human)

Compounds (21)

CompoundDefinitionClassesRoles
niacinNiacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3
antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
ursolic acidhydroxy monocarboxylic acid;
pentacyclic triterpenoid
geroprotector;
plant metabolite
torcetrapib(trifluoromethyl)benzenes;
carbamate ester;
quinolines
anticholesteremic drug;
CETP inhibitor
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
delta-8-tetrahydrocannabinol1-benzopyran
orlistatorlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.

Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.
beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative
anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source

alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group.
1,4-benzoquinones;
ansamycin;
carbamate ester;
secondary amino compound;
tertiary amino compound
Hsp90 inhibitor
tanespimycinCP 127374: analog of herbimycin A1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
dalcetrapibdalcetrapib: inhibits cholesteryl ester transfer protein (CETP)anilide
am-411
sc 795
3-((3-(4-chloro-3-ethylphenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol3-((3-(4-chloro-3-ethylphenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol: inhibits cholesteryl ester transfer protein; structure in first source
amg 3AMG 3: structure in first source
km-233KM-233: used for the treatment of high-grade glioma; structure in first source
mk 0354
anacetrapib
humaninhumanin: suppresses neuronal cell death induced by the Swedish mutant of amyloid precursor protein; suppresses neuronal cell death induced by three different types of FAD genes and amyloid beta; amino acid sequence in first source
gdc 0941pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
skepinone-lskepinone-L: a dibenzosuberone-type p38 MAPK inhibitor; structure in first source
evacetrapibbenzazepine
xen445